After exiting Chapter 11 protection for which it had filed in 2020, Akorn has announced that it will commence a review of strategic alternatives for its consumer health business. According to the company, which is now operating as a private entity under the legal name, Akorn Operating Company LLC, “this strategic review is a reflection of management’s continued focus on its prescription generic and branded drug portfolio.”
President and CEO Doug Boothe said “the consumer health brands represent a compelling business, marked by a strong and consistent...
